Patients on Mounjaro were both more likely to lose weight and saw larger reductions in body weight than patients on Ozempic.
confirmed that patients on Mounjaro, a drug approved for diabetes treatment, were both more likely to lose weight and saw larger reductions in body weight than patients on Novo Nordisk's Ozempic, which is approved for the same indication.
42% of tirzepatide patients lost at least 15% of their body weight, while about 18% of semaglutide patients achieved the same result.The study includes patients with overweight or obesity markers evaluated between May 2022 and September 2023.
Eli Lilly And Company Visuals Illustrations GLP-1
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsPeople taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.
Read more »
Study finds Mounjaro 'significantly more' effective than Ozempic for weight lossOverweight and obese adults using popular diabetes medications to suppress their appetites are 'significantly more likely' to shed pounds with Eli Lilly's Mounjaro than with Novo Nordisk's Ozempic, a new study has found, a result that could have major implications for one of the hottest new markets in the pharmaceutical field.
Read more »
Eli Lilly Blasts Use of Mounjaro and Zepbound for “Cosmetic Weight Loss”Science and Technology News and Videos
Read more »
Mounjaro bests Ozempic for weight loss in first head-to-head comparison of real-world useIn the first head-to-head comparison of two blockbuster drugs, patients taking Mounjaro lost more weight than those taking Ozempic.
Read more »
Ozempic vs. Mounjaro: New study reveals which is better to combat obesityBeyond Traditional Diet Pills: Groundbreaking New Weight Loss Drug Is More Effective Than Current Treatments
Read more »
Mounjaro Drug Tirzepatide Could Treat Sleep Apnea, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »